# US 2022/0008384 A1 · Composition comprising capsaicin or a capsacinoid for postoperative pain control

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008384 A1
- Document ID: US20220008384A1
- Status: Published application
- Kind: A1
- Application number: 17/486,065
- Filed: 2021-09-27
- Published: 2022-01-13
- Earliest claimed: 2019-03-28
- Assignees: Mestex AG
- Applicants: Mestex AG
- Inventors: Christian GERBER; Thomas GILLER; Olivier VALDENAIRE
- Web page: https://patentgrep.com/patent/US20220008384A1

## CPC

- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 23/00: Anaesthetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition comprising capsaicin or a capsacinoid is used in a method for postoperative pain control. The composition is administered to a site intended for surgery in a patient at least one day before surgery is actually performed.

## Claims

### Claim 1

A method for postoperative pain control in a patient in need thereof, said method comprising administering a composition to a site intended for surgery in said patient at least one day before surgery is actually performed, wherein the composition comprises capsaicin or a capsacinoid.

### Claim 2 (depends on 1)

Method according to claim 1, wherein the administering of the composition occurs at least 1 week before surgery.

### Claim 3 (depends on 2)

Method according to claim 2, wherein the administering of the composition occurs at least 1 month before surgery.

### Claim 4 (depends on 1)

Method according to claim 1, wherein the administering of the composition is repeated several times preoperatively.

### Claim 5 (depends on 1)

Method according to claim 1, wherein the capsacinoid is selected from the group consisting of resiniferatoxin, N-vanillylnonanamides, N-vanillylsulfonamides, N-vanillylureas, N-vanillylcarbamates, N[(substituted phenyl)methyl]alkylamides, methylene substituted [(substituted phenyl)methyl]alkanamides, N[(substituted phenyl)methyl]-cis-monosaturated alkenamides, N[(substituted phenyl)methyl]diunsaturated amides, 3-hydroxyacetanilide, hydroxyphenylacetamides, pseudocapsaicin, , homocapsaicin, homodihydrocapsaicin, transcapsaicin, civamide, nonivamide, olvanil, N-oleyl-homovanillamidia, dihydrocapsaicin, nordihydrocapsaicin anandamide, piperine, zingerone, warburganal, polygodial, aframodial, cinnamodial, cinnamosmolide, cinnamolide, isovelleral, scalaradial, ancistrodial, [beta]-acaridial, merulidial, scutigeral, and combinations thereof.

### Claim 6 (depends on 1)

Method according to claim 1, wherein a dose of 500-2000 micrograms of capsaicin is administered.

### Claim 7 (depends on 1)

Method according to claim 1, wherein a dose of 20-5000 ng of resiniferatoxin is administered.

### Claim 8 (depends on 1)

Method according to claim 1, wherein a dose of local anesthetic is administered prior to, simultaneously with or posteriorly to the capsaicin or a capsacinoid administration.

### Claim 9 (depends on 8)

Method according to claim 8, wherein the local anesthetic is administered 1 to 15 minutes prior to the capsaicin or a capsacinoid administration.

### Claim 10 (depends on 8)

Method according to claim 8, wherein the local anesthetic is administered as a solution of 0.5 to 100 ml of the local anesthetic.

### Claim 11 (depends on 10)

Method according to claim 10, wherein the local anesthetic and a concentration of the local anesthetic in the solution is as follows:
for Lidocain 0.5 to 5%;
for ropivacaine 0.1 to 5%;
for bupivacaine 0.1 to 5%;
for tetracaine 0.1 to 5%;
for prilocain, etidocaine or procaine 0.1 to 5%; and
for mepivacain or levobupivacaine 0.5 to 5%.

### Claim 12 (depends on 1)

Method according to claim 1, wherein the capsaicin or capsacinoid is dissolved in a carrier selected from the group consisting of sodium chloride solution for injection, Ringer's solution for injection, isotonic dextrose, sterile water dextrose solution, Lactated Ringers injection solution, distilled water, and mixtures thereof.
